Overview

An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term

Status:
Completed
Trial end date:
2018-02-24
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of controlled-release dinoprostone vaginal insert (DVI) for cervical ripening success (either Bishop Score (BS) ≥7 or vaginal delivery) within 12 hours of vaginal insert administration.
Phase:
Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Dinoprostone